Experiencia inicial de la reparación valvular mitral transcatéter
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
Degenerative MR is common, affecting ~600,000 persons in the U.S. Surgery is the standard of care, and is indicated for patients with symptoms or LV dysfunction. However, there are patients in whom the risk of surgery is prohibitive. The Mitraclip system received commercial approval in October 24, 201, being indicated for symptomatic patients with primary MR ≥3 and prohibitive surgical risk. Our objective was to analyze and report the initial commercial experience with the MitraClip System in the U.S.
PARTNER 1: Resultados a 5 años del implante percutáneo de válvula aórtica en pacientes con estenosis aórtica y alto riesgo quirúrgico
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Published in The Lancet.
Introduction
The Placement of Aortic Transcatheter Valves (PARTNER) trial showed that mortality at 1 year, 2 years, and 3 years is much the same with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) for high-risk patients with aortic stenosis. We report here the 5-year outcomes.
Ablación de la fibrilación auricular durante la cirugía mitral
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Published in NEJM
Introduction
Among patients undergoing mitral-valve surgery, 30 to 50% present with atrial fibrillation, which is associated with reduced survival and increased risk of stroke. Surgical ablation of atrial fibrillation has been widely adopted, but evidence regarding its safety and effectiveness is limited.
LEGACY: Efecto de la pérdida de peso en el control del ritmo en pacientes con fibrilación auricular
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Published in JACC
Introduction
Obesity and atrial fibrillation (AF) are dual epidemics that frequently coexist. Weight-loss reduces AF burden; however, whether this is sustained, has a dose effect or is influenced by weight-fluctuation is not known. The aim was to evaluate the long-term impact of weight-loss and weight-fluctuation on rhythm control in obese individuals with atrial fibrillation.
EMBRACE STEMI: Seguridad, tolerabilidad y eficacia de Bendavia en el daño por reperfusión en pacientes con SCACEST tratados mediante angioplastia primaria
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
Bendavia reduces ROS generation, protects cardiolipin, and preserves mitochondrial integrity and function in animal models of ischemia/reperfusion. The goal of this phase 2 trial was to assess the safety and efficacy of bendavia in acute myocardial infarction in humans.
Resultados clínicos y ecocardiográficos de la válvula SAPIEN 3 en pacientes con estenosis aórtica inoperables, de alto e intermedio riesgo
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
The SAPIEN 3 TAVR system is the newest iteration of balloon-expandable valve designed with an external fabric skirt to minimize paravalvular regurgitation (PVR). Two non-randomized registries were embedded in the PARTNER II trial to evaluate valve performance.
VII Reunión de Editores de Revistas Cardiovasculares Iberoamericanas
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
El domingo 15 de marzo de 2015 se reunió la Red de Editores de Revistas Cardiovasculares Iberoamericanas coincidiendo con la celebración del 64 Congreso del ACC en San Diego, con el objetivo de compartir experiencias y poner en marcha distintos proyectos conjuntos.
OSLER: Eficacia y seguridad de Evolocumab para reducir lípidos y eventos cardiovasculares
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Publicado en NEJM
Introduction
Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies. We conducted two extension studies to obtain longer-term data.
REGULATE PCI: Eficacia y seguridad del sistema anticoagulante REG1 comparado con bivalirudina en pacientes tratados con angioplastia coronaria
- Dr. Pablo Avanzas
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Introduction
The REG1 Anticoagulation System (Regado Biosciences) is a novel, aptamer-based, factor IXa inhibitor, pegnivacogin. Coupled with the reversible agent, anivamersen, this approach was developed for patients undergoing PCI. The safety and efficacy of REG1 compared with established anticoagulants is unknown.
SCOT-HEART: TAC coronario en pacientes con sospecha de angina secundaria a enfermedad coronaria
- Pablo Avanzas Fernández
- Cardiología Hoy
- Revista Española de Cardiología - Blog
Published in Lancet
Introduction
The benefit of CT coronary angiography (CTCA) in patients presenting with stable chest pain has not been systematically studied. We aimed to assess the eff ect of CTCA on the diagnosis, management, and outcome of patients referred to the cardiology clinic with suspected angina due to coronary heart disease.
Página 39 de 70
Vídeos del Editor
¿Quieres ver los vídeos del editor de REC Publications?
Encuéntralos aquí
Participa
A lo largo de los años, el blog de la SEC se ha revelado como un instrumento ideal para mantenerse al día de las novedades más importantes que se publican en las revistas científicas internacionales y estimular el debate entre los cardiólogos. Por ello, Cardiología hoy es un foro abierto a la participación de todos los profesionales de salud. Si quieres escribir un artículo...